Frontline Ltd FRO

NYS: FRO | ISIN: BMG3682E1921   25/04/2024
23,44 USD (+3,17%)
(+3,17%)   25/04/2024

29 februari 2024 · FRO – Q4 2023 Presentation · Persbericht

29 februari 2024 · FRO – Fourth Quarter and Full Year 2023 Results · Persbericht

22 februari 2024 · FRO – Invitation to Q4 2023 Results Conference Call and Webcast · Persbericht

22 februari 2024 · FRO – Invitation to Q4 2023 Results Conference Call and Webcast · Persbericht

12 januari 2024 · FRO – Sale of its five oldest VLCCs · Persbericht

12 december 2023 · FRO – 2023 Annual General Meeting · Persbericht

30 november 2023 · FRO – Q3 2023 Presentation · Persbericht

30 november 2023 · FRO – Third Quarter and Nine Months 2023 Results · Persbericht

24 november 2023 · FRO – Invitation to Q3 2023 Results Conference Call and Webcast · Persbericht

22 november 2023 · FRO – Closing under the Share Purchase Agreement with CMB NV · Persbericht

20 november 2023 · FRO – Notice of Annual General Meeting 2023 · Persbericht

10 november 2023 · FRO – 2023 Annual General Meeting · Persbericht

16 oktober 2023 · Thinking about buying stock in Ginkgo Bioworks Holdings, Ambrx Biopharma, Uranium Royalty Corp, Frontline Plc, or Femasys? · Persbericht

9 oktober 2023 · FRO – Investor Call Presentation · Persbericht

9 oktober 2023 · FRO – Investor Presentation – Fully funded acquisition of 24 modern VLCCs from Euronav NV · Persbericht

9 oktober 2023 · FRO – Fully funded acquisition of 24 modern VLCCs from Euronav NV · Persbericht

5 oktober 2023 · FRO – Reference to stock announcement by Euronav BV · Persbericht

14 september 2023 · FRO – Filing of Half Yearly Report · Persbericht

24 augustus 2023 · FRO – Q2 2023 Presentation · Persbericht

24 augustus 2023 · FRO – Second Quarter and Six Months 2023 Results · Persbericht

Mijn selecties